Lung Tuberculosis with Anti-Tuberculosis Drugs Safe Aspartate Aminotransferase Enzyme and Alanin Aminotransferase Enzyme

Makalew, Linda and Sukandar, Dyan. R and Rambi, Elne Vieke and Mambo, Deasy Estefine Yulike (2019) Lung Tuberculosis with Anti-Tuberculosis Drugs Safe Aspartate Aminotransferase Enzyme and Alanin Aminotransferase Enzyme. Proceeding 2nd Manado Health Polytechnic International Conference. pp. 102-104.

Text 945-Article Text-1823-2-10-20200416.pdf Download (156kB)

Abstract

Patients with pulmonary tuberculosis undergo Anti Tuberculosis Medication for at least 6 (six) months, this causes disruption of liver function or metabolism of the enzymes aspartate aminotransferase and alanine aminotransferase. This study aims to prove the safety of the enzymes of aspartate aminotransferase and alanine aminotransferase in patients with pulmonary tuberculosis who consume anti-tuberculosis drugs. This research is a descriptive type by taking 30 patients with tuberculosis in Ranotana Weru community health center in Manado, who are currently undergoing anti-tuberculosis drug therapy. The results obtained by all respondents were Serum Glutamic Oxaloacetic Transaminase <37 U/L and Serum Glutamic Pyruvate Transaminase was <65 U/L. The conclusion that can be drawn is that, as long as tuberculosis patients undergo anti-tuberculosis drug therapy maintaining food intake and regular exercise activities will not experience interference with the metabolism of the enzymes aspartate aminotransferase and alanine aminotransferase. It is recommended that further studies look at liver function in patients with drug resistant tuberculosis.

Item Type:	Article
Subjects:	Penelitian
Depositing User:	Admin Poltekkes
Date Deposited:	02 May 2023 08:18
Last Modified:	02 May 2023 08:18
URI:	http://repository.poltekkes-manado.ac.id/id/eprint/1133

Actions (login required)

View Item